Health systems across the Asia-Pacific are increasingly leveraging generic medications to reduce costs. While the rise in the use of generic medications is admirable, we’re not convinced that a sole focus on the current approach will ultimately serve the triple win vision required to deliver evolved health systems. This article explains in greater detail the challenges faced by the generic drug manufacturing industry, and therefore considerations for Asia-Pacific country leaders as they re-set their health reform ambitions in the post-pandemic era. There is an opportunity to leverage the off-patent trend through a proper collective effort, to create public-private win-win-win ecosystems that are built for sustainability. 

Connect with us